Loading…
Taizhou maker of generic active ingredients, best known for sartan blood-pressure drugs, plus contract (CDMO) work and finished formulations.
Taizhou maker of generic active ingredients, best known for sartan blood-pressure drugs, plus contract (CDMO) work and finished formulations.
Earns most of its income selling sartan blood-pressure ingredients and intermediates to generic drugmakers, with international buyers such as Teva and Sandoz taking much of it. It is adding contract development and manufacturing for other drug companies and its own finished tablets to lessen reliance on bulk ingredients.
Moat: narrow (regulatory licence, process know-how). European CEP and other regulatory filings plus process know-how; ingredient prices remain competitive.
Headquarters: Taizhou, China · Founded: 2003 · Employees: 4,686
Size Zhejiang Tianyu Pharmaceutical (300702.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.08B, the 2162nd largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥20.65 on 6 Nov 2026.
Performance Over six months the shares fell 2.1%, against -15.9% for the median peer and -16.4% for the China market (cap-weighted) — 4th highest of 21 in its peer set.
Growth Revenue grew 27.2% over the last twelve months (peer median +8.0%); the operating margin is 4.0% (peer median 8.7%).
Valuation It trades at 22.7× forward earnings against a peer median of 22.4× (8th cheapest of 15).
Price implies For today's price to make sense, revenue must grow about 5% a year for seven years (Req g). Recent delivered growth is +3%, so the hurdle is +2 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 0.5 points above its cost of capital (5.6% WACC).
Next results Next results expected around 16 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥3.79B | CN¥3.04B | CN¥2.62B | CN¥2.51B | CN¥2.66B |
| Revenue growth | — | +16% | +4% | -6% | — |
| Gross profit | CN¥1.40B | CN¥1.02B | CN¥810M | CN¥889M | CN¥603M |
| EBITDA | n/a | CN¥559M | CN¥444M | CN¥453M | CN¥176M |
| Net income | CN¥69.3M | CN¥140M | CN¥55.9M | CN¥27.4M | -CN¥119M |
| Free cash flow | CN¥506M | CN¥116M | CN¥176M | -CN¥361M | -CN¥575M |
| Capital expenditure | CN¥337M | CN¥358M | CN¥169M | CN¥317M | CN¥527M |
| Total debt | CN¥2.34B | CN¥2.16B | CN¥2.37B | CN¥2.14B | CN¥1.99B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Zhejiang Tianyu Pharmaceutical 300702.SZ | $1.08B | -2% | +27% | 4% | 22.7× | 5.0% |
| Zhejiang Huahai Pharmaceutical 600521.SS | $3.86B | +8% | +10% | 12% | 22.1× | 7.3% |
| Aurobindo Pharma AUROPHARMA.NS | $10.9B | +22% | +14% | 15% | 22.4× | 21.0% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 300702.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -7.3% | -6.1% | 11th highest of 21 |
| 6-month return | -2.1% | -15.9% | 4th highest of 21 |
| Distance from 52-week high | -25.7% | -35.5% | 7th highest of 21 |
| Revenue growth (TTM) | +27.2% | +8.0% | 5th highest of 20 |
| Operating margin | 4.0% | 8.7% | 8th lowest of 20 |
| Forward P/E | 22.7× | 22.4× | 8th cheapest of 15 |
| Growth the price implies (Req g, 7 yrs) | 5.0% | 4.4% | 7th least demanding of 13 |
| Growth delivered (Del g) | +3.5% | +5.7% | 6th lowest of 13 |
| Hurdle (Req g minus delivered) | +1.5 pp | +1.4 pp | 7th least demanding of 13 |
| ROIC minus cost of capital | +0.5 pp | -0.4 pp | 7th highest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Zhejiang Tianyu Pharmaceutical 300702.SZ | China | $1.08B | -2% | +27% | 4% | 22.7× | 5.0% | +3.5% |
| Sichuan Huiyu Pharmaceutical 688553.SS | China | $1.07B | -15% | +8% | 7% | n/a | 34.1% | -6.0% |
| CStone Pharmaceuticals 2616.HK | Hong Kong | $1.07B | -38% | +117% | -89% | n/a | n/a | n/a |
| Viyash Scientific VIYASH.NS | India | $1.07B | +3% | +96% | 13% | 30.3× | 38.6% | +20.4% |
| BeBetter Med 688759.SS | China | $1.08B | -49% | n/a | n/a | n/a | n/a | n/a |
| Basilea Pharmaceutica BSLN.SW | Switzerland | $1.07B | +27% | +5% | 24% | 12.4× | -5.7% | +12.7% |
| Chengdu Easton Biopharmaceuticals 688513.SS | China | $1.09B | -35% | -2% | 13% | 26.5× | 5.5% | +7.7% |
| Genfleet Therapeutics (Shanghai) 2595.HK | Hong Kong | $1.07B | -47% | -55% | -457% | n/a | n/a | n/a |
| China Resources Boya Bio-pharmaceutical 300294.SZ | China | $1.06B | -18% | -27% | -19% | 23.8× | n/a | n/a |
| Chongqing Taiji Industry (Group) 600129.SS | China | $1.09B | -15% | -4% | 2% | 26.5× | n/a | n/a |
| Renhe Pharmacy 000650.SZ | China | $1.06B | -10% | -7% | 14% | 17.7× | -9.4% | -7.0% |
| Jiangxi Fushine Pharmaceutical 300497.SZ | China | $1.10B | -29% | +103% | 24% | 10.6× | 8.6% | -4.5% |
| Ningbo Menovo Pharmaceutical 603538.SS | China | $1.10B | -51% | +19% | 9% | 49.2× | 13.9% | +4.9% |
| Bio-Thera Solutions 688177.SS | China | $1.10B | -14% | +24% | -44% | n/a | n/a | n/a |
| Jiangsu Kanion Pharmaceutical 600557.SS | China | $1.05B | -6% | +8% | 7% | 21.0× | 3.4% | +1.8% |
| Blue Jet Healthcare BLUEJET.NS | India | $1.11B | +13% | -28% | 28% | 32.5× | 49.0% | +13.8% |
| Sunflower Pharmaceutical 002737.SZ | China | $1.04B | -13% | +31% | -7% | 4.8× | -6.4% | -7.7% |
| Shandong Lukang Pharmaceutical 600789.SS | China | $1.11B | -13% | -7% | 3% | n/a | 3.3% | +6.5% |
| ST Pharm 237690.KS | South Korea | $1.12B | -52% | +26% | 18% | 27.9× | n/a | n/a |
| Towa Pharmaceutical 4553.T | Japan | $1.03B | -16% | +7% | 9% | 7.0× | 1.5% | +12.1% |
| SAWAI 4887.T | Japan | $1.03B | -22% | +11% | 9% | 10.9× | n/a | n/a |